Celcuity Inc. Common Stock
CELCCelcuity Inc. (CELC) is a biotechnology company focused on developing personalized cancer therapies through its innovative molecular and cellular analysis platform. The company utilizes its proprietary diagnostic technology to identify specific patient subgroups, enabling targeted treatments and improving clinical outcomes. Celcuity aims to translate complex biological data into actionable insights for better cancer treatment strategies.
Company News
Celcuity announced FDA approval of REVTORPYK (gedatolisib), the first pan-PI3K and mTORC1/2 inhibitor, for treating HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutations. In the Phase 3 VIKTORIA-1 trial, the drug reduced disease progression or death risk by 76% when combined with palbociclib and fulvestrant, and 67% with...
Celcuity Inc., a clinical-stage biotechnology company, announced the pricing of an upsized $500 million convertible senior notes offering due 2032, increased from the previously announced $400 million. The company plans to use net proceeds of approximately $484.3 million to repay Oxford Finance debt and fund working capital, clinical trials, and ...
Celcuity stock rose nearly 4% after analyst Silvan Turkcan from Citizens initiated coverage with a 'market outperform' rating and $150 price target. The bullish outlook centers on gedatolisib, the company's investigational breast cancer drug, which is less than two months away from FDA review completion. The analyst highlighted the drug's potenti...
Celcuity stock rose over 4% after releasing its 2025 financial results, beating analyst expectations with a narrower-than-expected net loss of $0.73 per share versus the projected $1.05. The clinical-stage biotech, which has no revenue, significantly improved its cash position to $166 million from $22.5 million at end-2024, providing substantial ...
Deerfield Management Company increased its stake in Celcuity by 980,470 shares (worth $80.6 million) in Q4, bringing its total position to $170.95 million. Celcuity's stock has surged 1,040% over the past year as the FDA accepted its new drug application for gedatolisib in breast cancer treatment with a decision date of July 17, 2026.
